Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: | Recruiting |
---|---|
Conditions: | Cancer, Brain Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/6/2019 |
Start Date: | July 18, 2018 |
End Date: | January 1, 2021 |
Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
This randomized phase III trial studies cabozantinib S-malate to see how well it works
compared with placebo in treating patients with neuroendocrine tumors previously treated with
everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in
the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known
as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when
blocked, may slow tumor growth.
compared with placebo in treating patients with neuroendocrine tumors previously treated with
everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in
the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known
as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when
blocked, may slow tumor growth.
PRIMARY OBJECTIVES:
I. To determine whether cabozantinib S-malate (cabozantinib) can significantly improve
progression-free survival (PFS) compared to placebo in patients with advanced pancreatic
neuroendocrine tumors (NET) whose disease has progressed after treatment with everolimus.
II. To determine whether cabozantinib can significantly improve progression-free survival
(PFS) compared to placebo in patients with advanced carcinoid tumors whose disease has
progressed after treatment with everolimus.
SECONDARY OBJECTIVES:
I. To determine whether cabozantinib can significantly improve overall survival (OS) compared
to placebo in patients with advanced pancreatic NET whose disease has progressed after
treatment with everolimus.
II. To determine whether cabozantinib can significantly improve overall survival (OS)
compared to placebo in patients with advanced carcinoid tumors whose disease has progressed
after treatment with everolimus.
III. To evaluate safety and tolerability of cabozantinib versus placebo in patients with
advanced pancreatic NET using Common Terminology Criteria for Adverse Events (CTCAE) and
Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events
(PRO-CTCAE).
IV. To evaluate safety and tolerability of cabozantinib versus placebo in patients with
advanced carcinoid tumors using CTCAE and PRO-CTCAE.
V. To evaluate the overall radiographic response rate of cabozantinib versus placebo in
patients with advanced pancreatic NET whose disease has progressed after treatment with
everolimus.
VI. To evaluate the overall radiographic response rate of cabozantinib versus placebo in
patients with advanced carcinoid tumors whose disease has progressed after treatment with
everolimus.
TERTIARY OBJECTIVES:
I. Results of the primary analysis will be examined for consistency, while taking into
account the stratification factors and/or covariates of baseline quality of life (QOL) and
fatigue.
II. To compare overall quality of life, disease-related symptoms, and other domains between
the two treatment groups (cabozantinib versus [vs.] placebo) within each cohort of patients
(pancreatic NET vs. carcinoid tumor). (Quality of Life Substudy Objective - A021602-HO1)
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO QD on days 1-28. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 12 weeks until disease
progression or start of new anticancer therapy, and then every 6 months until 8 years after
registration.
I. To determine whether cabozantinib S-malate (cabozantinib) can significantly improve
progression-free survival (PFS) compared to placebo in patients with advanced pancreatic
neuroendocrine tumors (NET) whose disease has progressed after treatment with everolimus.
II. To determine whether cabozantinib can significantly improve progression-free survival
(PFS) compared to placebo in patients with advanced carcinoid tumors whose disease has
progressed after treatment with everolimus.
SECONDARY OBJECTIVES:
I. To determine whether cabozantinib can significantly improve overall survival (OS) compared
to placebo in patients with advanced pancreatic NET whose disease has progressed after
treatment with everolimus.
II. To determine whether cabozantinib can significantly improve overall survival (OS)
compared to placebo in patients with advanced carcinoid tumors whose disease has progressed
after treatment with everolimus.
III. To evaluate safety and tolerability of cabozantinib versus placebo in patients with
advanced pancreatic NET using Common Terminology Criteria for Adverse Events (CTCAE) and
Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events
(PRO-CTCAE).
IV. To evaluate safety and tolerability of cabozantinib versus placebo in patients with
advanced carcinoid tumors using CTCAE and PRO-CTCAE.
V. To evaluate the overall radiographic response rate of cabozantinib versus placebo in
patients with advanced pancreatic NET whose disease has progressed after treatment with
everolimus.
VI. To evaluate the overall radiographic response rate of cabozantinib versus placebo in
patients with advanced carcinoid tumors whose disease has progressed after treatment with
everolimus.
TERTIARY OBJECTIVES:
I. Results of the primary analysis will be examined for consistency, while taking into
account the stratification factors and/or covariates of baseline quality of life (QOL) and
fatigue.
II. To compare overall quality of life, disease-related symptoms, and other domains between
the two treatment groups (cabozantinib versus [vs.] placebo) within each cohort of patients
(pancreatic NET vs. carcinoid tumor). (Quality of Life Substudy Objective - A021602-HO1)
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO QD on days 1-28. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 12 weeks until disease
progression or start of new anticancer therapy, and then every 6 months until 8 years after
registration.
Inclusion Criteria:
- Documentation of Disease:
- Histologic Documentation: Well- or moderately-differentiated neuroendocrine
tumors of pancreatic and non-pancreatic (i.e. carcinoid) origin by local
pathology
- The pathology report must state ONE of the following: 1) well- or
moderately-differentiated neuroendocrine tumor, 2) low- or
intermediate-grade neuroendocrine tumor, or 3) carcinoid tumor or atypical
carcinoid tumor; documentation of histology from a primary or metastatic
site is allowed
- Patients with poorly differentiated neuroendocrine carcinoma, high-grade
neuroendocrine carcinoma, adenocarcinoid tumor, or goblet cell carcinoid
tumor are not eligible
- Stage: Locally advanced/unresectable or metastatic disease
- Tumor Site: Histological documentation of neuroendocrine tumor of pancreatic,
gastrointestinal (GI), lung, or unknown primary site; GI, lung, and unknown
primary NETs will enroll in the carcinoid tumor cohort of the study
- Functional (associated with a clinical hormone syndrome) or nonfunctional
tumors are allowed
- Radiologic Evaluation: Target lesions must have shown evidence of disease
progression by Response Evaluation Criteria in Solid Tumors (RECIST) version
(v)1.1 criteria in the 12 months prior to registration; the radiologic images,
imaging reports, and clinic notes indicating growth of existing lesions,
development of new lesions, or treatment changes must be submitted
- Measurable Disease
- Patients must have measurable disease per RECIST 1.1 by computer tomography (CT)
scan or magnetic resonance imaging (MRI)
- Lesions must be accurately measured in at least one dimension (longest diameter
to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes);
non-measurable disease includes disease smaller than these dimensions or lesions
considered truly non-measurable including: leptomeningeal disease, ascites,
pleural or pericardial effusion, lymphangitic involvement of skin or lung
- Prior Treatment
- Patient must have failed at least one prior systemic therapy that included
everolimus; disease progression or treatment intolerance leading to
discontinuation is considered treatment failure
- Prior treatment (except somatostatin analogs) with biologic therapy,
immunotherapy, chemotherapy, investigational agent for malignancy, and/or
radiation must be completed at least 28 days prior to registration
- Prior treatment with somatostatin analogs is allowed, and continuation of
treatment with somatostatin analogs while on cabozantinib/placebo is allowed
provided that the patient has been on a stable dose for at least two months
- Prior systemic treatment with radionuclide therapy must be completed at least 6
weeks prior to registration
- Prior treatment with hepatic artery embolization (including bland embolization,
chemoembolization, and selective internal radiation therapy) or ablative
therapies is allowed if measurable disease remains outside of the treated area or
if there is documented disease progression in a treated site; prior
liver-directed or other ablative treatment must be completed at least 28 days
prior to registration
- Prior treatment with cabozantinib is not allowed
- Patients should have resolution of any toxic effects of prior therapy (except
alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0,
grade 1 or less
- Patients must have completed any major surgery at least 12 weeks prior to
registration and any minor surgery (including uncomplicated tooth extractions) at
least 28 days prior to registration; complete wound healing from major surgery
must have occurred at least 28 days prior to registration, and complete wound
healing from minor surgery must have occurred at least 10 days prior to
registration
- Patient History
- No class III or IV congestive heart failure (CHF) within 6 months of registration
- No clinically significant cardiac arrhythmia within 6 months of registration
- No unstable angina or MI within 6 months of registration
- No thromboembolic events within 6 months of registration (including [incl.]
stroke, transient ischemic attack [TIA], deep vein thrombosis [DVT], & pulmonary
embolism [PE])
- No known history of congenital long QT syndrome
- No uncontrolled hypertension within 14 days of registration (defined as systolic
blood pressure [SBP] >= 150 mmHg and/or diastolic blood pressure [DBP] >= 90 mmHg
despite optimal medical management)
- No clinically significant GI bleeding within 6 months of registration
- No clinically significant gastrointestinal abnormalities that may increase the
risk for gastrointestinal bleeding within 6 months of registration including, but
not limited to: active peptic ulcer, known endoluminal metastatic lesion(s) with
history of bleeding, inflammatory bowel disease, or other gastrointestinal
conditions with increased risk of perforation
- No GI perforation within 6 months of registration
- No known tumor invading the GI tract within 28 days of registration
- No radiologic or clinical evidence of pancreatitis
- No known cavitary lung lesions
- No known endobronchial lesions involving the main or lobar bronchi and/or lesions
infiltrating major pulmonary vessels that increase the risk of pulmonary
hemorrhage; (CT with contrast is recommended to evaluate such lesions)
- No hemoptysis greater than 1/2 teaspoon (2.5 mL) or any other signs of pulmonary
hemorrhage within the 3 months prior to registration
- No known tumor invading or encasing any major blood vessels
- No history of non-healing wounds or ulcers within 28 days of registration
- No history of fracture within 28 days of registration
- No brain metastases or cranial epidural disease unless adequately treated,
stable, and off steroid support for at least 4 weeks prior to registration
- No known medical condition causing an inability to swallow oral formulations of
agents
- No history of allergic reaction attributed to compounds of similar chemical or
biological composition to cabozantinib/placebo
- No "currently active" second malignancy other than non-melanoma skin cancers or
cervical carcinoma in situ; patients are not considered to have a "currently
active" malignancy if they have completed therapy and are free of disease for >=
3 years
- Concomitant Medications
- Other planned concurrent investigational agents or other tumor directed therapies
(chemotherapy, radiation) are not allowed while on this study
- Concurrent use of somatostatin analogs while on cabozantinib/placebo is allowed
provided that the patient has been on a stable dose for at least two months
- Full dose oral anticoagulation/antiplatelet therapy is not permitted; low dose
aspirin =< 81 mg/day is allowed; anticoagulation with therapeutic doses of low
molecular weight heparin (LMWH) is allowed in patients who are on a stable dose
of LMWH for at least 6 weeks prior to registration; treatment with warfarin is
not allowed; anticoagulation in patients with brain metastases is not permitted
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed;
patients must discontinue the drug at least 14 days prior to registration on the
study
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed;
patients must discontinue the drug at least 14 days prior to the start of study
treatment
- Not pregnant and not nursing
- Women of childbearing potential must have a negative pregnancy test done =< 14
days prior to registration
- A female of childbearing potential is a sexually mature female who: 1) has not
undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
postmenopausal for at least 12 consecutive months (i.e. has had menses at any
time in the preceding 12 consecutive months)
- Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Hemoglobin >= 9 g/dL
- Platelet count >= 100,000/mm^3
- Prothrombin time (PT)/ international normalized ratio (INR), partial thromboplastin
time (PTT) < 1.3 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 3 x ULN
- Total bilirubin =< 1.5 x ULN
- Except in the case of Gilbert disease, in which case total bilirubin must be =< 3
x ULN
- Creatinine =< 1.5 mg/dL OR creatinine clearance >= 45 mL/min
- Albumin >= 2.8 g/dL
- Potassium within normal limits (WNL)
- Phosphorus WNL
- Calcium WNL
- Magnesium WNL
- Urine protein to creatinine (UPC) ratio =< 1
- QT interval corrected for heart rate using Fridericia's formula (QTcF) =< 500 msec
- Thyroid-stimulating hormone (TSH) WNL
- Supplementation is acceptable to achieve a TSH WNL; in patients with abnormal
TSH, if free T4 is normal and patient is clinically euthyroid, patient is
eligible
We found this trial at
297
sites
Auburn, New York 13021
Principal Investigator: Jeffrey J. Kirshner
Phone: 315-472-7504
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Heloisa P. Soares
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Jennifer A. Chan
Phone: 773-702-9171
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Jennifer A. Chan
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Renuka V. Iyer
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Liudmila N. Schafer
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Heloisa P. Soares
Phone: 505-272-0530
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-757-0343
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Jennifer A. Chan
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Matthew H. Kulke
Phone: 617-638-8265
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Burlingame, California 94010
Principal Investigator: Ari D. Baron
Phone: 650-696-4487
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Keith E. Stuart
Phone: 781-744-8027
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Chih-Yi Liao
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
31500 Telegraph Road
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Bhavana Konda
Phone: 800-293-5066
Click here to add this to my saved trials
5100 W Broad St
Columbus, Ohio 43228
Columbus, Ohio 43228
(614) 544-1000
Principal Investigator: Timothy D. Moore
Phone: 614-566-3275
Doctors Hospital Nationally recognized for care quality and patient safety and satisfaction, Doctors Hospital is...
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
Click here to add this to my saved trials
810 Jasonway Avenue
Columbus, Ohio 43214
Columbus, Ohio 43214
614/442-3130
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Columbus Oncology and Hematology Associates Inc Columbus Oncology and Hematology Associates is a group of...
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
1203 South Tyler Street
Covington, Louisiana 70433
Covington, Louisiana 70433
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Principal Investigator: Nikolaos Trikalinos
Phone: 800-600-3606
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
561 West Central Avenue
Delaware, Ohio 43015
Delaware, Ohio 43015
(740) 615-1000
Principal Investigator: Timothy D. Moore
Phone: 740-615-0227
Delaware Health Center-Grady Cancer Center As the center of healthcare in Delaware County, Grady Memorial...
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80206
Principal Investigator: Keren Sturtz
Phone: 877-225-5654
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Robert J. Behrens
Phone: 515-282-2200
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
Des Moines, Iowa 50309
Principal Investigator: Robert J. Behrens
Phone: 515-282-2921
Click here to add this to my saved trials
Click here to add this to my saved trials
Easley, South Carolina 29640
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
17900 23 Mile Road
East China Township, Michigan 48054
East China Township, Michigan 48054
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
East Stroudsburg, Pennsylvania 18301
Principal Investigator: Tareq Al Baghdadi
Phone: 570-422-1700
Click here to add this to my saved trials
East Syracuse, New York 13057
Principal Investigator: Jeffrey J. Kirshner
Phone: 315-472-7504
Click here to add this to my saved trials
6401 France Ave S
Edina, Minnesota 55435
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
1202 East Locust Street
Emmett, Idaho 83617
Emmett, Idaho 83617
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
501 E. Hampden Ave.
Englewood, Colorado 80113
Englewood, Colorado 80113
303-788-5000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Englewood, Colorado 80113
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
Eureka, Illinois 61530
309-467-2371
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
Flint, Michigan 48503
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
302 Kensington Ave
Flint, Michigan 48503
Flint, Michigan 48503
(810) 762-8490
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Genesys Hurley Cancer Institute Bringing the most advanced cancer treatment services, technologies and programs available...
Click here to add this to my saved trials
302 Kensington Avenue
Flint, Michigan 48503
Flint, Michigan 48503
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
802 Kenyon Road
Fort Dodge, Iowa 50501
Fort Dodge, Iowa 50501
Principal Investigator: Robert J. Behrens
Phone: 515-574-8302
Click here to add this to my saved trials
39400 Paseo Padre Parkway
Fremont, California 94538
Fremont, California 94538
(510) 248-3000
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
Kaiser Permanente - Fremont You can rely on Kaiser Permanente for quality care, delivered with...
Click here to add this to my saved trials
3200 Kearney Street
Fremont, California 94538
Fremont, California 94538
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Fresno, California 93720
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
Click here to add this to my saved trials
550 Osborne Rd NE
Fridley, Minnesota 55432
Fridley, Minnesota 55432
(763) 236-5000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Unity Hospital Unity Hospital is one of the Twin Cities
Click here to add this to my saved trials
Fruitland, Idaho 83619
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
3315 N Seminary St
Galesburg, Illinois 61401
Galesburg, Illinois 61401
309-344-9269
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Golden, Colorado 80401
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Goldsboro, North Carolina 27534
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
Click here to add this to my saved trials
Grand Island, Nebraska 68803
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Grand Junction, Colorado 81502
Principal Investigator: Keren Sturtz
Phone: 773-702-9171
Click here to add this to my saved trials